Surrozen, Inc.
171 Oyster Point Boulevard
Suite 400
South San Francisco
California
94080
United States
Tel: 650-475-2820
Website: http://surrozen.com/
About Surrozen, Inc.
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. Surrozen was founded by five leading-edge scientists: K. Christopher Garcia, Ph.D., Roel Nusse, Ph.D. and Calvin Kuo, M.D., Ph.D. from Stanford University; Claudia Janda, Ph.D. from the Princess Maxima Center for Pediatric Oncology; and Hans Clevers, M.D, Ph.D. from the Hubrecht Institute and Princess Maxima Center. Each has conducted extensive research on Wnt signaling, with findings that together shape Surrozen’s technology and approach to therapeutic development.
15 articles with Surrozen, Inc.
-
Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference
11/12/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced that Craig Parker, president and chief executive officer of Surrozen, will be presenting at the Stifel 2020 Virtual Healthcare Conference.
-
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
10/15/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to support development of SZN-043, a novel liver-targeted regenerative antibody.
-
Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference
9/16/2020
Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine
-
Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports
8/19/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced a peer-reviewed publication describing its novel platform for the generation of potent and selective R-spondin mimetics. The article, “Tissue-targeted R-spondin mimetics for liver regeneration” was
-
UPDATE -- Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical TrialsIND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease
6/19/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful completion of a $50 million Series C financing
-
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical TrialsIND Candidates Nominated for the Treatment of Liver Disease and Inflammatory Bowel Disease
6/19/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced the successful completion of a $50 million Series C financing.
-
Surrozen and Lonza Announce Partnership for the Development and Manufacture of Surrozen’s Novel Wnt Activating Antibodies
6/2/2020
Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, and Lonza today announced that the companies have signed a collaboration agreement.
-
Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration
5/4/2020
Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online
-
Surrozen Announces Publication of Antibody Platform Technology in Cell Chemical Biology
3/30/2020
Novel approach to creating Wnt-mimetics establishes proof-of-concept for targeted regenerative antibodies
-
Surrozen to Present at Cowen and Company 40th Annual Health Care Conference
3/2/2020
Surrozen, Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies to repair a broad range of tissues, today announced that President & Chief Executive Officer, Craig Parker, will present at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts.
-
Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates
3/14/2019
Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the successful completion of a $50 million Series B financing.
-
Surrozen Strengthens Leadership Team with Addition of New CEO and Scientific Co-founder
4/4/2018
Surrozen, a preclinical-stage company advancing drug candidates that promote the repair and regeneration of human tissues, today announced two appointments to expand its leadership team. Craig Parker, a biotech industry veteran recently of Jazz Pharmaceuticals, has been appointed CEO, and Hans Clevers, M.D., Ph.D., professor of molecular genetics at the Hubrecht Institute, has been appointed scientific co-founder of Surrozen.
-
What You Need to Know About Surrozen
1/24/2018
Headquartered in South San Francisco, Surrozen focuses on developing drugs by leveraging insights into the Wnt signaling pathway. -
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
-
Bay Area Biotech Surrozen Launches With $33 Million and Could Double Its Headcount by Next Year
2/17/2017